ArticleJournal of virology2009
Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.
Article in Journal of virology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.Oncotarget · 2015Trial
- Viruses of avian origin demonstrate potential for cancer virotherapy.Archives of virology · 2026Article
- Cancer viroimmunotherapy platforms based on varicella-zoster virus and cytomegalovirus.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Review
- Immunological Impact of Oncolytic Adenoviruses On Cancer Therapy: Clinical Insights.European journal of immunology · 2025Review
- Review
- Oncolytic viruses: a potential breakthrough immunotherapy for multiple myeloma patients.Frontiers in immunology · 2024Review
- Therapy with oncolytic viruses: progress and challenges.Nature reviews. Clinical oncology · 2023Review
- Syrian hamster as an ideal animal model for evaluation of cancer immunotherapy.Frontiers in immunology · 2023Review
- Effects of pre-existing anti-adenovirus antibodies on transgene expression levels and therapeutic efficacies of arming oncolytic adenovirus.Scientific reports · 2022Article
- Multiple Treatment Cycles of Neural Stem Cell Delivered Oncolytic Adenovirus for the Treatment of Glioblastoma.Cancers · 2021Article
- Animal Models in Human Adenovirus Research.Biology · 2021Review
- Biographical Feature: William S. M. Wold, Ph.D., 1944-2021.Journal of virology · 2021Article
- The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?Expert opinion on drug discovery · 2021Review
- Efficient antitumor effects of a novel oncolytic adenovirus fully composed of species B adenovirus serotype 35.Molecular therapy oncolytics · 2021Article
- Species D Adenoviruses as Oncolytic Viral Vectors.Viruses · 2020Article
- Therapeutic Vaccines and Cancer Immunotherapy.Vaccines · 2020Article
- Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy.Nature communications · 2019Article
- Single-cycle adenovirus vectors in the current vaccine landscape.Expert review of vaccines · 2018Review
- Comparison of Liver Detargeting Strategies for Systemic Therapy with Oncolytic Adenovirus Serotype 5.Biomedicines · 2017Article
- Oncolytic Virotherapy: A Contest between Apples and Oranges.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Immune responses against adenovirus (Ad) vectors pose a possible concern for the outcome of treatment efficacy. To address the role of preexisting immunity in oncolytic Ad vector antitumor efficacy following intratumoral injection of vector as well as tumor-to-tissue spread of the vector, we employed the Syrian hamster model. These animals are immunocompetent, and their tumors and tissues are permissive for replication of Ad type 5 (Ad5). We used the adenovirus death protein-overexpressing Ad5-based vector INGN 007. Subcutaneous tumors were established in groups of hamsters that were or were not immunized with Ad5. Half of the hamsters in these groups were immunosuppressed with cyclophosphamide. For all groups, tumors injected with INGN 007 grew significantly more slowly than those injected with buffer. Under immunocompetent conditions, there was no significant effect of preexisting immunity on vector antitumor efficacy. Soon after the tumors in naïve animals were injected with vector, the hamsters developed neutralizing antibody (NAb) and the difference in NAb titers between the naïve and immunized groups diminished. Under immunosuppressed conditions, preexisting NAb did significantly reduce vector efficacy. Thus, NAb do reduce vector efficacy to some extent, but immunosuppression is required to observe the effect. Regarding vector toxicity, there was spillover of vector from the tumor to the liver and lungs in naïve immunocompetent hamsters, and this was nearly eliminated in the immunized hamsters. Thus, preexisting immunity to Ad5 does not affect INGN 007 antitumor efficacy following intratumoral injection, but immunity prevents vector spillover from the tumor to the liver and lungs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.